Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up - Should You Buy?
Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up - Should You Buy...
MarketBeat·1d ago
More News
Structure Therapeutics (GPCR) Expected to Announce Quarterly Earnings on Thursday
Structure Therapeutics (NASDAQ:GPCR) will be releasing its Q1 2026 earnings after the market closes on Thursday, May 7. (View Earnings Report at...
MarketBeat·2d ago
Universal Beteiligungs und Servicegesellschaft mbH Buys 67,338 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR
Universal Beteiligungs und Servicegesellschaft mbH grew its stake in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 428.5% during the 4th quarter, according to its most...
MarketBeat·3d ago
Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the nineteen research firms that are covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell rating...
MarketBeat·3d ago
VKTX Stock Outpaces LLY, ALT Ahead Of Earnings – Retail Eyes Breakout Ahead
VKTX rose about 1.4% over the past month, beating Altimmune, Amgen, and Structure Therapeutics; however, Novo Nordisk led the pack with a 17.3% gain.
Stocktwits·5d ago
Peregrine Capital Management LLC Buys Shares of 84,324 Structure Therapeutics Inc. Sponsored ADR $GPCR
Peregrine Capital Management LLC bought a new stake in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) during the fourth quarter, according to the company in its most recent...
MarketBeat·8d ago
VKTX Stock Draws Fresh Attention Ahead Of Earnings: Wall Street Sees Over 170% Upside As GLP-1 Race Burns Hot
Competition in the GLP-1 race is intensifying as Structure and Altimmune advance rival candidates, while Lilly, Novo and Amazon’s new medical platform expand in the GLP-1 market.
Stocktwits·10d ago
Structure Therapeutics (NASDAQ:GPCR) Upgraded by Wall Street Zen to Hold Rating
Wall Street Zen upgraded Structure Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday...
MarketBeat·15d ago
LLY's Oral GLP-1 Pill Foundayo Shows Heart Benefits in Diabetes Study
LLY's oral GLP-1 pill Foundayo shows cardiovascular benefits, weight loss, and strong glucose lowering in a phase III study as the FDA seeks more safety data.
Zacks·15d ago
LLY Stock Down as FDA Asks for More Safety Data on Oral Obesity Pill
LLY stock slips after FDA seeks added safety data on its new oral obesity pill Foundayo, raising questions despite blockbuster sales hopes.